Global Metagenomics Market Analysis 2023-2027: Breakthrough Insights in Medical Treatment and Microbiome Research by Application, Technology, Product and User
16 janv. 2024 11h18 HE
|
Research and Markets
Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User. With Executive and Consultant Guides. 2023...
Epigenetics Market Predicted to Garner USD 12.7 Billion By 2033, At CAGR 19.2% | Exclusive Report by Marketresearch.biz
16 janv. 2024 03h58 HE
|
MarketResearch.biz
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The epigenetics market was valued at USD 2.3 billion in 2023 with a significant growth and is projected to reach at USD 12.7 billion by 2033 with a CAGR...
Global Epigenetics Market Poised for Rapid Growth - Asia-Pacific Region to Witness Extensive Expansion by 2028
03 janv. 2024 09h03 HE
|
Research and Markets
Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The "Global Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method...
Cancer Tumor Profiling Market Size Worth USD 32.72 Billion by 2032 | Emergen Research
11 déc. 2023 08h15 HE
|
Emergen Research
Vancouver, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Cancer Tumor Profiling Market is expected to reach USD 32.72 Billion by 2032, according to a new report by Emergen Research. This market's growth is...
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
21 nov. 2023 12h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
16 nov. 2023 06h00 HE
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
Epic Bio to Participate in Upcoming Investor Conference
07 nov. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26 oct. 2023 11h09 HE
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...